<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="396">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00939315</url>
  </required_header>
  <id_info>
    <org_study_id>196/08</org_study_id>
    <secondary_id>Swissmedic 2009DR3123</secondary_id>
    <nct_id>NCT00939315</nct_id>
  </id_info>
  <brief_title>Multimodal Diagnostic Assessment of Cerebral Gliomas With FET &amp; FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy</brief_title>
  <acronym>Gliomes-FLP</acronym>
  <official_title>Impact of Multimodal Diagnostic Assessment of Cerebral Gliomas With F-18-fluoroethyl-L-tyrosine PET/CT, F-18-fluorocholine PET/CT and Magnetic Resonance Imaging and Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lionel Perrier Foundation (Montreux, Switzerland)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <authority>Switzerland: Federal Office of Public Health</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish the diagnostic value of
      O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET-CT, [18F]-fluorocholine (FCH) and magnetic
      resonance imaging (MRI) combined with magnetic resonance spectroscopy (MRS) in patients with
      suspected cerebral glioma using neuronavigated biopsies with histopathological analysis as
      reference. FET combined with MRS may be a powerful, widely applicable new method to improve
      the diagnosis of cerebral gliomas. The extent to which FCH and MRS provide similar
      information is not known precisely and this study will establish their respective diagnostic
      value in differentiating tumoral from non-tumoral tissue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Ability of image-guided biopsy using FET, FCH PET/CT and MRS information to target the most representative sites of tumor grade as compared to histopathological examination</measure>
    <time_frame>On the biopsy day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with glioma suspicion referred for biopsy to our university hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspicion of intracerebral glioma on MR

          -  Men of women

          -  Age &gt;18, no upper limit as long as a biopsy or intervention is foreseen

        Exclusion Criteria:

          -  Need of rapid intervention in &lt;2 weeks

          -  Previous neurosurgical intervention (biopsy, shunt, etc.) or any other cerebral
             treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John O Prior, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois and University of Lausanne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John O Prior, PhD MD</last_name>
    <phone>+41 21 314 4348</phone>
    <email>john.prior@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Nicod Lalonde, MD</last_name>
    <phone>+41 21 314 4373</phone>
    <email>marie.nicod@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>CH</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 16, 2012</lastchanged_date>
  <firstreceived_date>July 14, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>John O. Prior</investigator_full_name>
    <investigator_title>Professor and Head of Department</investigator_title>
  </responsible_party>
  <keyword>Glioma, diagnosis</keyword>
  <keyword>Imaging</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
